Resistance to Proteasome Inhibitors in Cancer (eBook)
XI, 390 Seiten
Springer International Publishing (Verlag)
978-3-319-06752-0 (ISBN)
The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.
This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.
Q. Ping Dou, Ph.D. is Professor of Pathology, Cancer Biology and Pharmacology at Wayne State University School of Medicine. Dr. Dou's laboratory is one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. He also serves on multiple editorial boards, including The Open Leukemia Journal, Journal of Clinical Oncology, Frontiers of Bioscience, to name a few.
Q. Ping Dou, Ph.D. is Professor of Pathology, Cancer Biology and Pharmacology at Wayne State University School of Medicine. Dr. Dou's laboratory is one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. He also serves on multiple editorial boards, including The Open Leukemia Journal, Journal of Clinical Oncology, Frontiers of Bioscience, to name a few.
Preface - Q Ping Dou Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer - Sara M. Schmitt, Rahul R. Deshmukh, Q. Ping DouResistance to proteasome inhibitors in multiple myeloma - Francesca Cottini MD, Anna Guidetti MD, Claudia Paba Prada MD, Teru Hideshima MD PhD, Michelle Maglio, Cindy Varga MD, Dharminder Chauhan JD PhD, Jacob Laubach MD, Kenneth C Anderson MD, Paul G Richardson MDOvercoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma - Hans C. Lee, M.D., and Robert Z. Orlowski, Ph.D., M.D.Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis - Jeffrey A. Zonder, MDProfiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy - Amit Mitra, Holly Stessman, John Shaughnessy, and Brian Van NessTargeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition - Michael Batalo, Prithviraj Bose, Beata Holkova, Steven GrantPre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies - Jacqueline Cloos, Denise Niewerth, Gerrit JansenOvercoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches - Jason I. Kass, Jennifer R. Grandis and Daniel E. JohnsonTargeting the proteasome pathway for the treatment of solid tumors - Nisar Ahmad, Elias Anaissie and James J. Driscoll
Erscheint lt. Verlag | 16.9.2014 |
---|---|
Reihe/Serie | Resistance to Targeted Anti-Cancer Therapeutics | Resistance to Targeted Anti-Cancer Therapeutics |
Zusatzinfo | XI, 390 p. 55 illus., 51 illus. in color. |
Verlagsort | Cham |
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Studium |
Naturwissenschaften ► Biologie | |
Technik | |
Schlagworte | 20S proteasome inhibitors • antibacterial drug resistance • Bortezomib • carfizomib • leukemia • multiple myeloma • ubiquitin-proteasome pathway |
ISBN-10 | 3-319-06752-4 / 3319067524 |
ISBN-13 | 978-3-319-06752-0 / 9783319067520 |
Haben Sie eine Frage zum Produkt? |
![PDF](/img/icon_pdf_big.jpg)
Größe: 6,8 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich